Relevant bibliographies by topics / Anticoagulants

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Anticoagulants'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 September 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anticoagulants.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anticoagulants"

1

Shelfer, Janet, David Zapala, and Larry Lundy. "Fall Risk, Vestibular Schwannoma, and Anticoagulation Therapy." Journal of the American Academy of Audiology 19, no. 03 (March 2008): 237–45. http://dx.doi.org/10.3766/jaaa.19.3.8.

Full text
Abstract:
Elderly patients with balance problems are at high risk for falls. When these same patients are also on anticoagulants, the consequences of a fall can be serious. Anticoagulant therapy increases the risk of cerebral hemorrhage. Even mild head trauma can cause a fatal cerebral hemorrhage when anticoagulants are used. However, this risk needs to be weighed against the possibility of spontaneous stroke. The decision to choose anticoagulant therapy can become even more complicated if the patient has an increased risk of falling. A case is presented of an 87-year-old female with balance problems, in part from a small unilateral vestibular schwannoma. She was also receiving Coumadin anticoagulant therapy. When she began to fall, a decision had to be made about the relative risks and benefits of Coumadin therapy. The risk/benefit calculation could change, however, depending on whether her fall risk could be improved. This article presents the diagnostic test results and medical opinions surrounding this case. The importance of assessing patients' overall situation is stressed in planning rehabilitation. Los pacientes ancianos con problemas del equilibrio tienen un alto riesgo para caídas. Cuando esos mismos pacientes toman anticoagulantes, las consecuencias de una caída pueden ser serias. La terapia anticoagulante aumenta el riesgo de una hemorragia cerebral. Aún un trauma cefálico leve puede causar una hemorragia cerebral fatal cuando se usan anticoagulantes. Sin embargo, este riesgo debe ser ponderado contra la posibilidad de una apoplejía espontánea. La decisión de escoger una terapia anticoagulante puede volverse aún más complicada si el paciente tiene un riesgo aumentado de caídas. Se presenta un caso de una mujer de 87 años de edad con problemas de equilibrio, en parte por un pequeño schwanoma vestibular unilateral. Ella también estaba recibiendo terapia con el anticoagulante Coumadin. Cuando ella empezó a caerse, se tuvo que tomar una decisión sobre el riesgo relativo y los beneficios de la terapia con Coumadin. El cálculo del riesgo/beneficio podría cambiar, sin embargo, dependiendo de si su riesgo para caídas puede ser mejorado. Este artículo presenta los resultados de las pruebas diagnósticas y las opiniones médicas al respecto del caso. La importancia de evaluar la situación global del paciente se enfatiza a la hora de planear la rehabilitación.
APA, Harvard, Vancouver, ISO, and other styles
2

Jose Vicente Catalá Ripoll, Jose Ángel Monsalve Naharro, Esther Domingo Chiva, Pablo Cuesta Montero, and Jose María Jiménez Vizuete. "Terapia antitrombótica en pacientes con hemorragia intracraneal. ¿Revertimos?" Revista Electrónica AnestesiaR 10, no. 8 (August 31, 2018): 6. http://dx.doi.org/10.30445/rear.v10i8.599.

Full text
Abstract:
Realizamos una revisión de la guía de práctica clínica de la reversión de la terapia antitrombótica en pacientes con hemorragia intracraneal que hayan recibido terapia antiagregante, anticoagulante o fibrinolítica. Se analizan recomendaciones para la reversión de antagonistas de vitamina K, anticoagulantes orales de acción directa, heparinas no fraccionadas y de bajo peso molecular, trombolíticos y antiagregantes plaquetarios, en el contexto de una hemorragia intracraneal. ABSTRACT Review the clinical practice guidelines for the reversal of antithrombotic therapy in patients with intracranial hemorrhage with antiplatelet, anticoagulant or fibrinolytic therapy. We analyzed the most important recommendations for the reversal of vitamin K antagonists, direct-acting oral anticoagulants, unfractionated and low-molecular-weight heparins, thrombolytics and platelet antiaggregants, in the context of an intracranial hemorrhage.
APA, Harvard, Vancouver, ISO, and other styles
3

Teruya, Jun, Aaron G. West, and Mary Nell Suell. "Lupus Anticoagulant Assays: Questions Answered and to Be Answered." Archives of Pathology & Laboratory Medicine 131, no. 6 (June 1, 2007): 885–89. http://dx.doi.org/10.5858/2007-131-885-laaqaa.

Full text
Abstract:
Abstract Context.—Lupus anticoagulants are antibodies with heterogenous specificities to phospholipids. They have been associated with clinical syndromes consisting of thrombosis and recurrent fetal loss. Objective.—To address questions about the laboratory assay aspects of lupus anticoagulants. This review is intended for clinicians managing lupus anticoagulant testing in clinical laboratories. Data Sources.—Published literature on lupus anticoagulants, with emphasis on laboratory assay methods. Conclusions.—Although there are published criteria for confirming the presence of a lupus anticoagulant, there is no consensus on assay methods for lupus anticoagulant testing. The mixing study is a useful screening test for lupus anticoagulants, but it may have limited utility. Clinical context may necessitate the performance of factor assays in addition to lupus anticoagulant testing to rule out factor deficiency or factor-specific inhibitor. Additionally, the presence of different anticoagulants may affect the reliability of lupus anticoagulant assays. Lupus anticoagulants are an independent risk factor for thrombosis. It may be useful to use different assays when there is clinical suspicion for a lupus anticoagulant. When testing for lupus anticoagulants, clinicians must carefully consider the clinical context because factor assays may also be indicated.
APA, Harvard, Vancouver, ISO, and other styles
4

Moore, Gary W., Savita Rangarajan, and Geoffrey F. Savidge. "The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies." Clinical and Applied Thrombosis/Hemostasis 14, no. 3 (June 19, 2008): 332–37. http://dx.doi.org/10.1177/1076029607305099.

Full text
Abstract:
Lupus anticoagulants are a heterogeneous group of autoantibodies detected by their effects on phospholipid-dependent coagulation assays. Persistent lupus anticoagulants are associated with thrombotic disease, but not all are clinically significant. Antibody heterogeneity and reagent and test variability dictate that at least 2 tests, of different types, should be used to screen lupus anticoagulants. The objective of this study was to investigate whether the activated seven lupus anticoagulant assay detects clinically significant antibodies. Eighty-two patients with antiphospholipid syndrome (APS) and 32 with systemic lupus erythematosus + positive for activated seven lupus anticoagulant and who were without thrombosis, who were positive by activated seven lupus anticoagulant assay, were investigated for lupus anticoagulants by dilute Russell's viper venom time, dilute activated partial thromboplastin time, and Taipan snake venom time, and for anticardiolipin antibodies. Fifty-seven of the APS patients were positive for lupus anticoagulants in multiple assays, 25 in activated seven lupus anticoagulant alone. Fourteen of the latter group were previously positive in other antiphospholipid antibodies assays, and 11 had only been positive for lupus anticoagulants by activated seven lupus anticoagulant. Twenty-eight had elevated anticardiolipin antibodies, 6 of whom were from the group that was positive in activated seven lupus anticoagulant only. Eight of the systemic lupus erythematosus + lupus anticoagulants (without thrombosis) patients were positive for lupus anticoagulant by activated seven lupus anticoagulant alone and had only been positive in activated seven lupus anticoagulant previously, and none had elevated anticardiolipin antibodies. The remaining 24 patients were lupus-anticoagulant positive in multiple assays, and 9 had elevated anticardiolipin antibodies. Dilute Russell's viper venom time and Dilute activated partial thromboplastin time are widely used to detect lupus anticoagulants and are considered to detect clinically significant antibodies. Activated seven lupus anticoagulant detected antibodies in APS patients who were positive by these assays and also lupus anticoagulants undetectable by the dilute Russell's viper venom time/dilute activated partial thromboplastin time reagents used, demonstrating its utility as a first-line or second-line assay.
APA, Harvard, Vancouver, ISO, and other styles
5

KADYSEVA, E. R. "Pharmacoeconomic aspects of the use of anticoagulants in a multi-speciality hospital." Practical medicine 20, no. 6 (2022): 58–60. http://dx.doi.org/10.32000/2072-1757-2022-6-58-60.

Full text
Abstract:
The article presents the dynamics of the consumption of oral anticoagulants and direct-acting anticoagulants for 2019–2021 in the Republic Clinical Hospital of the Republic of Tatarstan. Currently, anticoagulant therapy is very popular among clinicians. It is known that the economic component plays a rather important role in health care. The purpose — to analyze the costs of anticoagulant drugs in a multi-speciality hospital in 2019–2021. Material and methods. An analysis was made of the share of costs of direct-acting anticoagulants and oral anticoagulants in the total cost of medicines by years in a multi-speciality hospital using the Apteka 1C software. Results. There is a clear trend towards increased consumption of direct-acting anticoagulants and oral anticoagulants. The peak of consumption was observed in 2020 and 2021. Conclusions. The use of oral anticoagulants reduces direct costs compared to standard prophylaxis with direct anticoagulants.
APA, Harvard, Vancouver, ISO, and other styles
6

Cahill, Tom, Julie Broughton, Thomas Ferguson, and Stephen Jenkins. "The impact of the introduction of direct oral anticoagulants into a general practice and hospital anticoagulant services: two local service evaluations." British Journal of Healthcare Management 25, no. 6 (June 2, 2019): 1–12. http://dx.doi.org/10.12968/bjhc.2018.0060.

Full text
Abstract:
Background/Aims Anticoagulants are indicated for stroke prevention in nonvalvular atrial fibrillation, and treatment and prevention of venous thromboembolism. The aim of this study was to describe the impact of introducing direct oral anticoagulants on anticoagulation services. Methods One primary and one secondary care anticoagulation service evaluation compared pre-direct oral anticoagulant (2012) and post-direct oral anticoagulant introduction (2015). Findings In the secondary care service, anticoagulant monitoring clinics decreased by 20% and service capacity increased by 38.5% post-direct oral anticoagulant introduction. Direct oral anticoagulants comprised 87.6% of newly-initiated anticoagulants post-direct oral anticoagulant introduction. In patients newly initiated on anticoagulation, a total of 62 anticoagulation-related inpatient admissions were recorded in 12.6% of patients in the pre-direct oral anticoagulant period, compared with a total of 21 anticoagulation-related admissions in 3.6% of patients in the post-direct oral anticoagulant period. In the primary care service, warfarin comprised 62.9% of all anticoagulants prescribed post-direct oral anticoagulant introduction. Overall, patients attended a mean of 14.2 anticoagulation service visits in 6 months pre-direct oral anticoagulant and 13.3 visits in 6 months post-direct oral anticoagulant introduction (non-direct oral anticoagulant-treated: 16.1/patient; direct oral anticoagulant treated: 0.8/patient). Few patients were offered a choice of anticoagulant; however, overall patient satisfaction was high in both services. Conclusions Direct oral anticoagulant introduction in secondary care was associated with increased service capacity and decreased patient visits. Patient choice was limited; however, satisfaction was high in both services.
APA, Harvard, Vancouver, ISO, and other styles
7

Tatarsky, B. A., and N. V. Kazyonnova. "Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs." Russian Journal of Cardiology 26, no. 7 (August 8, 2021): 4482. http://dx.doi.org/10.15829/1560-4071-2021-4482.

Full text
Abstract:
The use of direct oral anticoagulants minimized the risks associated with vitamin K antagonist (warfarin) therapy. Currently, direct oral anticoagulants have priority over warfarin for the prevention of thromboembolic events in patients with atrial fibrillation and a number of other conditions requiring anticoagulant therapy. Direct oral anticoagulants along with antiarrhythmic therapy are the accepted strategy for atrial fibrillation treatment. At the same time, the effect of drug-drug interactions (DDI) between direct oral anticoagulants and antiarrhythmic drugs, which have common points of metabolic application, has not been fully elucidated. In order to provide effective and safe anticoagulant and antiarrhythmic therapy in patients with AF, it is important to understand the mechanisms and severity of DDI of direct oral anticoagulants and antiarrhythmic agents. This review discusses the issues of DDI of direct oral anticoagulants and antiarrhythmic drugs used to treat atrial fibrillation.
APA, Harvard, Vancouver, ISO, and other styles
8

Manfredini, Mattia, Pier Paolo Poli, Luca Creminelli, Alberto Porro, Carlo Maiorana, and Mario Beretta. "Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery." Journal of Clinical Medicine 10, no. 23 (November 25, 2021): 5526. http://dx.doi.org/10.3390/jcm10235526.

Full text
Abstract:
Objectives: A wide variety of approaches have been proposed to manage anticoagulant drugs in patients undergoing dental surgery; vitamin K antagonists and novel direct oral anticoagulants have been used. The present study aims to explore the existing evidence concerning the management of patients in anticoagulant therapy undergoing oral surgery procedures and to give suggestions related to peri- and post-operative measures. Materials and methods: A comprehensive search of databases was conducted to identify studies that evaluated the relationship between direct oral anticoagulants and dental procedures. The present scoping review was realized in adherence with the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. The publications varied from randomized controlled trials (RCT) to cohort trials. Only articles written in English language and published between 2000 to 2020 were screened. The studies were included if discussing the management of a patient in anticoagulant therapy (warfarin or direct oral anticoagulants) scheduled for tooth extraction. Results: 33 studies were selected and included in the qualitative review. Nineteen considered anticoagulant therapy with warfarin, six considered anticoagulant therapy with new oral anticoagulants and eight compared patients taking warfarin with patients taking direct oral anticoagulants. Conclusions: No case of extractive surgery should alter the posology of the drug: thromboembolic risks derived from discontinuation are heavier than hemorrhagic risks. Clinical relevance: direct oral anticoagulants are safer in terms of bleeding and manageability and bleeding episodes are manageable with local hemostatic measures.
APA, Harvard, Vancouver, ISO, and other styles
9

Yang, Peiwen. "Analysis of the therapeutic effect and application of anticoagulant drugs." Theoretical and Natural Science 15, no. 1 (December 4, 2023): 188–92. http://dx.doi.org/10.54254/2753-8818/15/20240480.

Full text
Abstract:
As the global population ages, the incidence of cardiovascular disease, stroke, and other diseases associated with thrombosis is also increasing, resulting in a great need for effective anticoagulant treatments. The purpose of this research is to summarize the development of anticoagulant drugs to date, including their drug types, version iterations, mechanisms of action, as well as current challenges and future development directions of anticoagulant drugs. The research will first review traditional anticoagulants, such as vitamin K antagonists and heparins, and discuss in detail their effects, advantages, and limitations. Next, it will give a detailed description of new anticoagulants, such as direct acting oral anticoagulants (DOACs), and analyse their advantages over traditional anticoagulants in terms of safety and efficacy. Finally, it will propose the strategy of individualized therapy for specific population and the combination therapy of anticoagulant therapy and other drugs, and look forward to the development of new anticoagulant drugs in the future. The application of anticoagulant drugs in medicine has a wide range of clinical significance. With the continuous deepening of research, new therapeutic strategies and drugs are constantly being developed and improved, aiming at providing more safe and effective anticoagulant therapy.
APA, Harvard, Vancouver, ISO, and other styles
10

Annisa, Lily, Nurfina Dian Kartikawati, and Vitarani Dwi Ananda Ningrum. "Use of anticoagulant drugs for hospitalised patients: A multicentre study." Pharmacy Education 24, no. 3 (May 12, 2024): 286–91. http://dx.doi.org/10.46542/pe.2024.243.286291.

Full text
Abstract:
Background: Anticoagulants are indicated for several types of diseases with progression related to coagulation. Patients administered this drug need to be evaluated by the pharmacist regarding its effectiveness and possible side effects. Objective: This research aimed to analyse the profile use of anticoagulants among patients at Yogyakarta Hospital. Method: This research was a multicentre study conducted retrospectively using the medical records of inpatients who received anticoagulants. Result: Among a total of 486 respondents, the majority were male (63.58%), and the adult age category (18-59 years) was 55.76%. Most anticoagulants were used in cases of cardiovascular disease, diagnosed with NSTEMI as much as 20.21%. The most used anticoagulant drug was heparin (48.9%), followed by fondaparinux (34.3%) and enoxaparin (16.8%). The most duration of anticoagulant use was one to four days (73.02%) with the dose range being 200-1000 units/day. Conclusion: Heparin was the anticoagulant widely used in patients with NSTEMI. Although the elderly were the group most at risk of ADR due to anticoagulants, most of these drugs were precisely taken by adults, who also required serious attention. Further research is needed to provide a more comprehensive approach to anticoagulant therapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anticoagulants"

1

Lloret, Dominique. "Les anticoagulants circulants spontanés anti facteur VIII:c. à propos d'un cas." Montpellier 1, 1989. http://www.theses.fr/1989MON11228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Llory, Pierre. "Actualité sur les anticoagulants circulants antithrombinase : incidences en anesthésie-réanimation." Montpellier 1, 1988. http://www.theses.fr/1988MON11372.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Moustafa, Farès. "Risque hémoragique sous anticoagulants : Vers une prise en charge personnalisée." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSES049/document.

Full text
Abstract:
Introduction. Devant les nombreux facteurs pouvant influencer le risque hémorragique despatients sous anticoagulant, le concept de médecine personnalisée pourrait avoir unimpact favorable dans la prise en charge globale de ces patients.Hypothèse et objectif. L’hypothèse de ce travail de thèse est que l’utilisation et l’analysede registre de « vraie vie » pourrait permettre de définir des « profils » hémorragique depatient permettant une prise en charge personnalisée des patients.Matériel et Méthode. Ce travail de thèse a utilisé deux registres de vraie vie, le registreRIETE (registre international multicentrique prospectif) et le registre RATED (registremonocentrique).Résultats. Nous avons montré l’importance du recueil biologique dans l’analyse desaccidents hémorragiques sous anticogulants avec une perte plus élevée de facteurs decoagulation, lors d’hémorragie gastro-intestinales par rapport aux intracraniennes sousAVK. A l’inverse, ce risque est diminué de moitié en cas de mutation du facteur V Leiden.Grâce au registre RIETE, nous nous sommes ensuite intéressés aux métrorragies sousanticoagulant (peu décrites dans la littérature) où seulement 0,17% des femmesprésentaient des saignements utérins majeurs. Nous avons par la suite montré que lespatients fragiles (CrCl ≤50 mL / min, un âge ≥75 ans ou un poids corporel ≤50 kg) ont unrisque deux fois plus élevé de saignement grave. Enfin, afin de montrer lacomplémentarité des registres de vraie vie et des données d’essais randomisés, nousnous sommes intéressés aux patients exclus de ces essais randomisés et avons montréégalement un risque hémorragique 4 fois plus élevé.Conclusion. Ce travail de thèse a permis de démontrer l’intérêt de travailler non pastoutes hémorragies confondues mais hémorragies par hémorragies, avec un intérêt deréalisation de registres prospectifs de vraie vie avec la mise en oeuvre de bio-banquepermettant une analyse plus personnalisée de la prise en charge des patients
Introduction. Given many risk factors that may influence the risk of hemorrhage underanticoagulant therapy, the concept of personalized medicine could have a favorableimpact in the overall management of these patients.Hypothesis and objective. The hypothesis of this thesis is that the use and analyze of "reallife" registries could allow to define hemorrhagic "profiles" allowing a personalizedmanagement of the patients.Material and method. This thesis work has used two real life registries, the RIETE registry(international, multicentric and prospective register) and RATED (monocentric register).Results. We showed the importance of biological database in the analysis of hemorrhagicevents under anticoagulants with a higher loss of coagulation factors in gastrointestinalbleeding compared with intracranial bleeding under AVK. Conversely, this bleeding risk istwo times lower in case of factor V Leiden mutation. Thanks to the RIETE registry, wewere interested in abnormal uterine bleeding under anticoagulant therapy (few studies inthe literature) with major uterine bleeding only for 0.17% of women. Then, we showed thatfragile patients (CrCl ≤50 mL / min, age ≥75 years or body weight ≤50 kg) have a 2-foldhigher risk for major bleeding. Finally, in order to show the complementarity between datafrom real life registries and randomized trial, we assessed patients normally excluded fromthese randomized trials and also showed a 4-fold higher bleeding risk in these excludedpatients.Conclusion. This thesis work allowed us to demonstrate the interest of working not only onoverall hemorrhages but on each type of hemorrhage separately, with a particular interestto create real life prospective registries with the implementation of bio-bank allowing amore personalized analysis of the intake of patients
APA, Harvard, Vancouver, ISO, and other styles
4

Mehta, Akul. "Synthetic, Sulfated, Lignin-Based Anticoagulants." VCU Scholars Compass, 2014. http://scholarscompass.vcu.edu/etd/598.

Full text
Abstract:
Chemoenzymatically synthesized low molecular weight lignin polymers have been previously found to be potent inhibitors of a number of serine proteases via allosteric mechanisms targeting heparin binding sites. Herein, we describe the creation of synthetic sulfated β-O4 lignin (SbO4L) polymer, which is more homogenous compared to previous lignins with respect to its inter-monomeric linkage. SbO4L is a selective inhibitor of thrombin and plasmin. SbO4L was found to act via a unique mechanism targeting thrombin exosite 2 in a manner similar to platelet glycoprotein Ibα (GPIbα). Advanced hemostasis and thrombosis assays demonstrated that SbO4L acts via a dual mechanism: as an anticoagulant, by allosteric inhibition of thrombin catalysis; and as an antiplatelet agent, by competing with platelet GPIbα. These mechanisms are comparable in potency to low molecular weight heparins currently used in the market, indicating that targeting exosite 2 may yield clinically useful drugs in the future. Since the β-O4 type lignin was found to be selective for thrombin and plasmin, we hypothesized that other scaffolds from lignins could be potent inhibitors of other serine proteases. In particular, we screened a library of synthetic sulfated small molecules against factor XIa – an emerging target for prophylactic anticoagulation. Our search identified a sulfated benzofuran trimer (a mimic of β-5 type linkage found in lignins) as a potent inhibitor of factor XIa. Surprisingly, this inhibitor did not compete with heparin. A plausible binding site in the A3 domain of factor XIa was proposed by using molecular modeling techniques. The binding pose demonstrated good correlation with the structure activity data from in vitro studies. Further confirmation that the apple domains were required was proved by testing the trimer against recombinant catalytic domain. A 40-fold decrease in activity was observed. A temperature-dependant perrin plot demonstrated that factor XIa undergoes a large conformational change in the presence of the trimer, which is possibly converting the enzyme back into the zymogen-like shape. In general, the synthetic sulfated lignins can act as a useful foundation to develop anticoagulant, antiplatelet, and anti-inflammatory molecules in the future.
APA, Harvard, Vancouver, ISO, and other styles
5

Hababou, Karine. "Les traitements de la maladie thromboembolique : intérêt de l'international normalized ratio (INR) pour leur surveillance." Paris 5, 1991. http://www.theses.fr/1991PA05P089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Campos, Nelson Leonardo Kerdahi Leite de [UNESP]. "Análise do controle de anticoagulação oral em pacientes portadores de próteses valvares cardícas mecânicas por meio de ambulatório especializado: experiência de 10 anos." Universidade Estadual Paulista (UNESP), 2006. http://hdl.handle.net/11449/100384.

Full text
Abstract:
Made available in DSpace on 2014-06-11T19:30:52Z (GMT). No. of bitstreams: 0 Previous issue date: 2006Bitstream added on 2014-06-13T19:00:52Z : No. of bitstreams: 1 campos_nlkl_dr_botfm.pdf: 1278066 bytes, checksum: 5a717660b8920b45a66421478ad3441e (MD5)
Fundação para o Desenvolvimento Médico e Hospitalar (Famesp)
Estudo realizado, com base nos dados do ambulatório, para controle de anticoagulação nos pacientes portadores de próteses valvares cardíacas mecânicas do Serviço de Cirurgia Cardiovascular do Hospital das Clínicas da Faculdade de Medicina de Botucatu, no intervalo de dez anos, com os objetivos: avaliação da resposta à terapêutica profilática anticoagulante; quantificação das complicações tromboembólicas e hemorrágicas, com estratificação de sua gravidade; comparação entre tipos de anticoagulantes orais, doses e efeitos; influência da posição da prótese; presença de fibrilação atrial e tamanho do átrio esquerdo; e análise da estratégia de anticoagulação adotada. Foram incluídos, no estudo, 259 pacientes portadores de próteses mitrais (mitrais), aórticas (aórticos) e mitral e aórticas (mitro-aórticos). Foram analisadas 9714 consultas com valores do tempo de protrombina (em RNI) e dados dos registros hospitalares sobre complicações tromboembólicas e hemorrágicas com graus de gravidade. Os pacientes foram divididos em quatro grupos de acordo com o porcentual de consultas em que a RNI se encontrava dentro do intervalo desejado. Foram estudados dois anticoagulantes (Fenprocumona e Warfarina) e suas dosagens. Foi, também, avaliada a ocorrência de complicações tromboembólicas e hemorrágicas. Os resultados estão apresentados em: número de pacientes com complicações, estudo atuarial e freqüência linearizada de ocorrência de eventos. Os dados obtidos permitiram concluir que: a anticoagulação oral foi mais satisfatória nos aórticos do que nos mitrais e mitro-aórticos; os mitrais apresentaram ocorrência de eventos tromboembólicos semelhante a dos aórticos, porém com maior freqüência de hemorragias; os grupos que tiveram anticoagulação mais estável apresentaram menos complicações; poucas diferenças quanto à ocorrência de...
The study was held using outpatient data collected during 10 years for anticoagulation control of patients with mechanical prosthetic heart valves from the Cardiovascular Surgery Service at the Medical University Hospital in Botucatu city. The objectives were as follows: evaluation of prophylactic anticoagulation therapy, number of thromboembolic and hemorrhagic complications and their severity stratification, assessment of different oral anticoagulants, their effects and dosing, influence of prosthesis position, presence of atrial fibrillation and size of the left atrium, assessment of the anticoagulation strategy. Two hundred and fifty nine patients with mitral (M), aortic (A), mitral and aortic (M-A) prostheses were included in the study. Prothrombin time expressed in terms of international normalised ratio (INR) from 9714 consultations, medical data on thromboembolic and hemorrhagic complications as well as their severity were evaluated. Patients were allocated to four groups according to percentage of consultations which INR was within the target range. Two anticoagulants (Fenprocoumon and Warfarin), their dosing system, thromboembolic and hemorrhagic complications were also evaluated. Results were expressed as: number of patients with complications, actuarial study and linearized rate of events. Conclusions: oral anticoagulation was better in A than in M or M-A patients; M patients presented as many thromboembolic events as A patients although with higher hemorrhagic rate; groups presenting more steady anticoagulation showed fewer complications; there were few differences concerning complications among users of Fenprocoumon and Warfarin; most patients needed lower anticoagulant doses; patients with atrial fibrillation and/or enlarged left atrium presented as many thromboembolic complications as the other studied patients, although with higher... (Complete abstract click electronic access below)
APA, Harvard, Vancouver, ISO, and other styles
7

Barrière, Véronique. "Présence d'un anticoagulant circulant chez un insuffisant rénal chronique." Montpellier 1, 1989. http://www.theses.fr/1989MON11217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pham, Thuy-Hang. "Thérapeutique anticoagulante dans un service de cardiologie : prescription et suivi thérapeutique." Paris 5, 1991. http://www.theses.fr/1991PA05P050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mueller, Tanja. "Use of direct oral anticoagulants in Scotland." Thesis, University of Strathclyde, 2017. http://digitool.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=28882.

Full text
Abstract:
Patients with atrial fibrillation (AF), a common arrhythmic disorder, are treated long-term with oral anticoagulants in order to prevent strokes. As warfarin treatment is associated with several problems, the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban, apixaban and edoxaban have been introduced. However, real-world information regarding the utilisation of DOACs as well as their clinical effectiveness and safety is still scarce. Hence, the aim of this project was to increase the evidence from clinical practice regarding the use of DOACs in patients with AF in Scotland. Methods: This study has been designed as a retrospective cohort study (study period 2009 – 2015), using routinely collected administrative data. Three databases – the Prescribing Information System (PIS); Scottish Morbidity records (SMR); and National Records of Scotland (NRS) – covering prescriptions dispensed in primary care, hospital episodes and death records, respectively, have been linked using Community Health Index (CHI) numbers, a unique patient identifier in Scotland. Based on this data, three analyses have been conducted: a description of DOAC prescribing over time; an evaluation of patients’ adherence to DOAC treatment; and an analysis of the comparative clinical effectiveness and safety of DOACs. Results: In Scotland, the number of patients being treated with DOACs has steadily been increasing, and in 2015, the number of incident DOAC patients exceeded those of warfarin. During the study period, 14,811 AF patients with a mean age of 74.1 years [SD 11.3] initiated DOAC treatment. Adherence to treatment was good overall, with a median Medication Refill Adherence (MRA) of 102.3% [IQR 90.1% – 112.5%]; discontinuation rates were however variable, ranging from 24.9% (apixaban) to 63.3% (dabigatran). Persistence rates 12 months after treatment initiation were 61.8%, 78.6%, and 83.6% among patients initiating treatment with dabigatran, rivaroxaban, and apixaban, respectively. All DOACs were similarly effective in preventing strokes and systemic embolisms – nevertheless, the overall bleeding risk was higher with rivaroxaban as compared to apixaban [HR 1.52, 95% CI 1.21 – 1.91]. Conclusion: DOACs have swiftly been accepted into clinical practice, and adherence to treatment is generally good. As all DOACs are similarly effective, decisions for or against a specific drug should be made based on a wider risk assessment, with a focus on bleeding risks.
APA, Harvard, Vancouver, ISO, and other styles
10

FONDO, JASKIEWICZ MARTINE. "Intoxications secondaires a l'ingestion de raticides anticoagulants." Reims, 1994. http://www.theses.fr/1994REIMM082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anticoagulants"

1

L, Poller, and Hirsh Jack 1935-, eds. Oral anticoagulants. London: Arnold, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Proietti, Riccardo, Ahmed AlTurki, Nicola Ferri, Vincenzo Russo, and T. Jared Bunch, eds. Direct Oral Anticoagulants. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-74462-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mousa, Shaker A. Anticoagulants, Antiplatelets, and Thrombolytics. New Jersey: Humana Press, 2003. http://dx.doi.org/10.1385/1592596584.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mousa, Shaker A., ed. Anticoagulants, Antiplatelets, and Thrombolytics. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-803-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

A, Mousa Shaker, ed. Anticoagulants, antiplatelets, and thrombolytics. Totowa, N.J: Humana Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

A, Mousa Shaker, ed. Anticoagulants, antiplatelets, and thrombolytics. Totowa, N.J: Humana Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mousa, Shaker A. Anticoagulants, antiplatelets, and thrombolytics. [Place of publication not identified]: Humana, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

1934-, Green David, ed. Anticoagulants: Physiologic, pathologic, and pharmacologic. Boca Raton: CRC Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

F, Bruley Duane, and Drohan William, eds. Protein C and related anticoagulants. The Woodlands, Tex: Portfolio Pub. Co., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shantsila, Eduard, and Gregory YH Lip. Non-Vitamin K Antagonist Oral Anticoagulants. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-25460-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Anticoagulants"

1

Yamashita, Tetsushi, and Toshihiro Torato. "Anticoagulants." In The Concise Manual of Apheresis Therapy, 161–74. Tokyo: Springer Japan, 2013. http://dx.doi.org/10.1007/978-4-431-54412-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Özkaya, Esen, and Kurtuluş Didem Yazganoğlu. "Anticoagulants." In Adverse Cutaneous Drug Reactions to Cardiovascular Drugs, 195–206. London: Springer London, 2014. http://dx.doi.org/10.1007/978-1-4471-6536-1_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shetty, Hamsaraj G. M., and Philip A. Routledge. "Anticoagulants." In Pathy's Principles and Practice of Geriatric Medicine, 357–62. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9781119952930.ch31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hallenbeck, William H., and Kathleen M. Cunningham-Burns. "Anticoagulants." In Pesticides and Human Health, 15. New York, NY: Springer New York, 1985. http://dx.doi.org/10.1007/978-1-4612-5054-8_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bhandari, Prasan. "Anticoagulants." In Pharmacology Mind Maps for Medical Students and Allied Health Professionals, 369–78. Boca Raton, FL : CRC Press/Taylor & Francis, 2020.: CRC Press, 2019. http://dx.doi.org/10.1201/9780429023859-40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fasinu, Pius S., and Stephanie A. Kustos. "Anticoagulants." In Encyclopedia of Molecular Pharmacology, 1–10. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-21573-6_166-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Scherer Hofmeier, Kathrin. "Anticoagulants." In Cutaneous Drug Hypersensitivity, 223–31. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-82743-4_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fasinu, Pius S., and Stephanie A. Kustos. "Anticoagulants." In Encyclopedia of Molecular Pharmacology, 125–34. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-57401-7_166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pauli, R. M. "Anticoagulants." In Drug Toxicity in Embryonic Development II, 191–229. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60447-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Coons, James C., and Sandeep Devabhakthuni. "Thrombolytics/Anticoagulants." In High-Risk IV Medications in Special Patient Populations, 1–67. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-606-1_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anticoagulants"

1

Pengo, V., M. J. Heine, P. Thiagarajan, and s. s. Shapiro. "A GENERAL MECHANISM FOR LUPUS ANTICOAGULANTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643660.

Full text
Abstract:
Although- a number of observations have implied that lupus anticoagulants have immunologic specificity towards anionic. phospholipids, thereby prolonging phospholipid-dependent coagulation tests, this assumption has been directly demonstrated in only one patient with a monoclonal IgM paraprotein. We have tested the generality of this hypothesis directly by isolating five IgG lupus anticoagulants from patients with lupus-like syndromes and/or thrombosis. IgG lupus anticoagulant fractions were isolated free of other plasma proteins and free of contaminating phospholipid by adsorption to and elution from cardiolipin-cholesterol-dicetylphosphate liposomes , followed by chromatography on protein A-Sepharose. Cardiolipin liposomes, but not phosphatidylcholine liposomes, were capable of removing all, or nearly all, lupus anticoagulant activity from patient plasma. Anticardiolipin and lupus anticoagulant activity were both present in acidic fractions on isoelectric focusing. F(ab’)2 fragments retained lupus anti coagulant activity and bound to cardiolipin in an ELISA assay. The affinity-purified IgG preparations reacted with cardiolipin, phosphatidyl serine , phosphatidylinositol and phosphatidic acid, but not with phosphatidylcholine or phosphatidyl ethanol amine, and inhibited calcium-dependent binding of prothrombin and of factor X to phosphatidy1serine-coated surfaces. These data demonstrate a general mechanism for the action of lupus anticoagulants: antibodies that have immunologic specificity towards anionic phospholipids, thereby blocking the calcium-mediated binding of vitamin K-dependent coagulation factors to coagulation-active phospholipid surfaces.
APA, Harvard, Vancouver, ISO, and other styles
2

Hetjens, S., J. Harenberg, and C. Weiss. "Interaction of direct oral anticoagulants and other anticoagulants on DOAC Dipstick test." In 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728173.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sagripant, A., A. Carpi, U. Baicchi, A. Nicolini, and M. Ferdeghint. "ORAL ANTICOAGULANTS IN BREAST CANCER PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643671.

Full text
Abstract:
As the fibrin clot may play a role in the intravascular metastatic spread of breast cancer, we have treated women with advanced breast cancer with oral anticoagulants. After mastectomy, 11 consentient women with postsurgical stage Nl (6 patients), N2 (3 patients) and N3 (2 patients) and without evidence of distantmetastasis have been treated with acenocoumarol (INR 2-4,5) for 4-22 months (mean 12 months). All the patients received adjuvant therapy (radiotherapy, polichemiotherapy and/or tamoxifen) in conformity with theclassic indications. FibrinopeptideA plasmatic level, checked in everyone on stable anticoagulation, was always lower than 2 ng/ml (mean 0,78 ng/ml). No major bleeding occurred, except a copious hematuria caused by overdosage. Until now all the 11 women are alive. Two of them stopped anticoagulant, one because of hemorrhagic cystitis, the other because of awareness of visceral metastases; all the other 9 women arebeing treated now. Three patients(2N2 and 1 N3) have evidence of visceral metastases; no sign of relapsehas been observed by serial instrumental and laboratory examinations inthe other 8 women. A control group of 13 patients (9 N2 and 4 N3)was compared with the group of anticoagulated patients in more advanced stages (2 N2 and 3 N3):The follow-up of the anticoagulatedNl patients is too brief as yet forcomparative evaluation. Our preliminary data seem to indicate an useful role of oral anticoagulants inbreast cancer and oblige us to prolong investigation.
APA, Harvard, Vancouver, ISO, and other styles
4

Molins, E. Rodriguez, B. Rodríguez de Castro, R. Pampín, B. Fernández González, Y. Labeaga Baramundi, S. Rodríguez Nebreda, and R. Sánchez del Moral. "5PSQ-015 Prescription errors of anticoagulants." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sepúlveda, R. López, S. Anaya-Ordóñez, E. Espínola García, MA García Lirola, MS Martín Sances, and J. Cabeza Barrera. "DI-023 Utilisation study of oral anticoagulants (2008–2015) and bleeding due to anticoagulant treatment (2012–2015)." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ren, Yujie, and Cheng Du. "The Research on Synthesis Methods of Anticoagulants." In 2012 International Conference on Biomedical Engineering and Biotechnology (iCBEB). IEEE, 2012. http://dx.doi.org/10.1109/icbeb.2012.441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gavilanes, Francisca, José Leonnidas Alves, Caio JC Fernandes, Luis FL Prada, William Salibe Filho, Mario Terra Filho, Carlos Jardim, and Rogério Souza. "The use of new anticoagulants in CTEPH." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2409.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Caspers, M., S. Roeschl, J. Holle, and H. Bendella. "Assessment of the anticoagulant effect of direct oral anticoagulants (DOACs) in patients needing immediate management during emergency procedures." In 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1728101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schofield, K. P., J. M. Thomson, and L. Poller. "PROTEIN C RESPONSE TO INDUCTION AND WITHDRAWAL OF ORAL ANTICOAGULANT TREATMENT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643273.

Full text
Abstract:
Protein C (PC) activity and antigen levels have been related to clotting activities of factors VII and X during the induction and withdrawal periods of oral anticoagulant treatment. Both factor VII and PC activities fell rapidly during a gradual induction regime of nicoumalone in six consecutive patients but factor VII showed a more rapid and much more marked depression than PC. In contrast reductions in factor X were much slower. PC antigen although depressed rapidly at the initiation of treatment did not subsequently fall to the same degree as PC activity, The ratio of activity to antigen became progressively smaller.In six further serial patients discontinued from long-term treatment with nicoumalone (mean duration 12-6 months) there was a reversal of the pattern, but with two important differences. Firstly, there was evidence of an excessive rise (“rebound”) of factor VII compared with the steady state levels in these patients; and secondly there was an unexpectedly slow return of PC activity and antigen to normal levels after the oral anticoagulant was withdrawn (levels were still below normal on day 4). Factor X also showed a slow rate of increase, similar to PC activity recovery. These observations lend support to gradual withdrawal of oral anticoagulants after a period of long-term administration. The results suggest that after discontinuation of long-term oral anticoagulants patients may have increased coagulability up to four days.
APA, Harvard, Vancouver, ISO, and other styles
10

Croci, D., M. Dalolio, M. Kamenova, R. Guzman, L. Mariani, S. Schaeren, and J. Soleman. "Novel Oral Anticoagulants in Patients Undergoing Spine Surgery." In Joint Annual Meeting 2018: Swiss Society of Neurosurgery, Swiss Society of Neuroradiology. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1660764.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Anticoagulants"

1

Purba, Abdul, Saraswati Gumilang, Dhihintia Jiwangga, Nurina Hasanatuludhhiyah, and Maarten Postma. Cost and clinical outcomes in the use of new oral anticoagulants versus warfarin in deep vein thrombosis: A systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0106.

Full text
Abstract:
Review question / Objective: What are the benefits of using new oral anticoagulants compared to warfarin in terms of efficacy, bleeding, and cost among people with deep vein thrombosis? This study aimed to compare the effectiveness, bleeding incidence, and cost between NOAC and warfarin in DVT patients. Condition being studied: The patient confirmed DVT with the results of the Wells' score and D-dimer test stating "possible DVT" and followed by an ultrasound examination which stated "DVT positive". Patients are taking oral anticoagulants to treat DVT or to prevent a recurrence. Oral anticoagulants consist of apixaban, rivaroxaban, edoxaban, dabigatran, and warfarin.
APA, Harvard, Vancouver, ISO, and other styles
2

Datta, Soumentra, James Worsfold, and Zafar Maan. Understanding direct oral anticoagulants: an update for urology practice. BJUI Knowledge, July 2019. http://dx.doi.org/10.18591/bjuik.0315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gillespie, Catherine W., and Leigh Purvis. Novel Anticoagulants Achieve Rapid Market Penetration despite Higher Costs. AARP Public Policy Institute, June 2021. http://dx.doi.org/10.26419/ppi.00100.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Biswas, Krishnendu, and Soumendra Datta. Understanding direct oral anticoagulants: an update for urology practice. BJUI Knowledge, January 2023. http://dx.doi.org/10.18591/bjuik.0315.v2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ye, Hao-Zhen, Jia-Jia Gao, He Zhou, Zhi-Wei Li, Hong-Wei Xu, and Ben Wang. The risk of postpolypectomy bleeding in patients receiving direct oral anticoagulants compared to warfarin or non-anticoagulants: a systematic review with meta-analysis of cohort studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bode, Arthur P. Development of Novel, Reversible, Non-Toxic Anticoagulants for Greatly Extended Platelet Storage. Fort Belvoir, VA: Defense Technical Information Center, September 1988. http://dx.doi.org/10.21236/ada203215.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

A, Bengolea, Chamorro F, Ozon N, Catalano HN, and Izcovich A. Effectiveness and safety of utilizing imaging techniques to guide treatment in patients with venous thromboembolism. Epistemonikos Interactive Evidence Synthesis, January 2023. http://dx.doi.org/10.30846/ies.2b03926263.v1.

Full text
Abstract:
Objective The objective of this systematic review is to perform a comprehensive evaluation of the efficacy and safety of the use of imaging to determine the duration of anticoagulant treatment in patients with thrombosis of any cause (idiopathic, resolved secondary or chronic) who have completed a period of 3 to 6 months of oral anticoagulant treatment. Methods In order to identify randomized clinical trials that evaluate our question of interest, we performed exhaustive searches in Epistemonikos and PubMed, from the date of creation of each source until February 2024. Additionally, we considered additional sources to identify trials that may not have been identified through electronic search. Two reviewers independently selected included studies, extracted data, and assessed risk of bias. We performed a quantitative synthesis (meta-analysis) and prepared summary tables of findings as recommended by the GRADE group. The results of this review were presented to a team of clinical experts from the medical clinic service of the German Hospital of Buenos Aires, who analyzed and made judgments for each of the proposed criteria within the framework of the evidence for the decision. After making judgments for each criterion, the experts formulated the clinical recommendation for the problem of interest. Result Through the search strategy, 514 references were identified and examined by title and abstract. Of these, 17 references were included for full-text evaluation. Finally, 2 randomized clinical trials were included. The evidence on the use of CT or venous Doppler to determine the duration of anticoagulation in patients with thromboembolic events of any type is very uncertain. The evidence on the use of tomography or venous Doppler to determine the duration of anticoagulation in patients with idiopathic thromboembolic events secondary to transient and/or chronic risk factors (patients with cancer) is very uncertain. Clinical recommendation The medical clinic service of the German Hospital [link_recommendation|recommendation](does not recommend using image-guided strategies to suspend anticoagulant treatment in patients with thromboembolisms) (CONDITIONAL RECOMMENDATION AGAINST, VERY LOW CERTAINTY IN THE EVIDENCE). Conclusions In this systematic review, we explored the usefulness of using imaging (tomography or venous Doppler) to determine the continuity of treatment with oral anticoagulants in patients with venous thrombosis. However, the evidence derived from the included studies has very low certainty.
APA, Harvard, Vancouver, ISO, and other styles
8

A, Bengolea, Chamorro F, Ozon N, Catalano HN, and Izcovich A. Effectiveness and safety of utilizing imaging techniques to guide treatment in patients with venous thromboembolism. Epistemonikos Interactive Evidence Synthesis, April 2024. http://dx.doi.org/10.30846/ies.2b03926263.

Full text
Abstract:
Objective The objective of this systematic review is to perform a comprehensive evaluation of the efficacy and safety of the use of imaging to determine the duration of anticoagulant treatment in patients with thrombosis of any cause (idiopathic, resolved secondary or chronic) who have completed a period of 3 to 6 months of oral anticoagulant treatment. Methods In order to identify randomized clinical trials that evaluate our question of interest, we performed exhaustive searches in Epistemonikos and PubMed, from the date of creation of each source until February 2024. Additionally, we considered additional sources to identify trials that may not have been identified through electronic search. Two reviewers independently selected included studies, extracted data, and assessed risk of bias. We performed a quantitative synthesis (meta-analysis) and prepared summary tables of findings as recommended by the GRADE group. The results of this review were presented to a team of clinical experts from the medical clinic service of the German Hospital of Buenos Aires, who analyzed and made judgments for each of the proposed criteria within the framework of the evidence for the decision. After making judgments for each criterion, the experts formulated the clinical recommendation for the problem of interest. Result Through the search strategy, 514 references were identified and examined by title and abstract. Of these, 17 references were included for full-text evaluation. Finally, 2 randomized clinical trials were included. The evidence on the use of CT or venous Doppler to determine the duration of anticoagulation in patients with thromboembolic events of any type is very uncertain. The evidence on the use of tomography or venous Doppler to determine the duration of anticoagulation in patients with idiopathic thromboembolic events secondary to transient and/or chronic risk factors (patients with cancer) is very uncertain. Clinical recommendation The medical clinic service of the German Hospital [link_recommendation|recommendation](does not recommend using image-guided strategies to suspend anticoagulant treatment in patients with thromboembolisms) (CONDITIONAL RECOMMENDATION AGAINST, VERY LOW CERTAINTY IN THE EVIDENCE). Conclusions In this systematic review, we explored the usefulness of using imaging (tomography or venous Doppler) to determine the continuity of treatment with oral anticoagulants in patients with venous thrombosis. However, the evidence derived from the included studies has very low certainty.
APA, Harvard, Vancouver, ISO, and other styles
9

Xu, Zhi-Qiang, Zhi-Hong Xu, and Na Zhang. Comprehensive Systematic Review and Meta-Analysis on Anticoagulants and Aspirin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2023. http://dx.doi.org/10.37766/inplasy2023.9.0089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Geng, Yu, Chang Meng, Tong Gao, Siyuan Li, Lei Bi, Yintang Wang, and Ping Zhang. The Efficacy and Safety of Novel Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Prevention: systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anticoagulants' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography